Michael S O'Reilly, M.D.
Department of Thoracic Radiation Oncology, Division of Radiation Oncology
About Dr. O'Reilly
Michael S. O’Reilly, MD is a Professor of Radiation Oncology at the University of Texas MD Anderson Cancer Center. He is a medical doctor who specializes in the treatment of thoracic malignancies with training in angiogenesis research, cancer biology, surgery, and radiation oncology. Dr. O’Reilly’s clinical practice is in radiation oncology as part of the Thoracic Radiation Oncology service at MD Anderson. Dr. O’Reilly also runs a research laboratory within the Department of Experimental Radiation Oncology. Dr. O’Reilly worked in the angiogenesis research laboratory of Professor Judah Folkman at Children’s Hospital Boston and Harvard Medical School and focused his research efforts upon the discovery and characterization of inhibitors of angiogenesis and tumor dormancy. He discovered multiple endogenous angiogenesis inhibitors including angiostatin, endostatin, and antiangiogenic antithrombin. Ongoing studies of the influence of tumor microenvironment upon response to angiogenesis inhibitors alone and in combination with other modalities are now underway in Dr. O’Reilly’s laboratory. Dr. O’Reilly and colleagues study the interaction of antiangiogenic agents and other targeted biologics with radiation therapy and chemotherapy in a series of projects designed to produce improved efficacy and diminished toxicity in the treatment of cancer. Dr. O’Reilly’s research work has led to multiple publications and presentations and has provided the basis for clinical trials in lung cancer patients.
Read More
Present Title & Affiliation
Primary Appointment
Professor, Department of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston
Dual/Joint/Adjunct Appointment
Professor, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston
Education & Training
Degree-Granting Education
| 1989 | Tufts University, Boston, Massachusetts, US, Medicine, MD |
| 1985 | Middlebury College, Middlebury, Vermont, US, Biology, BA |
Postgraduate Training
| 1996-2000 | Clinical Residency, Radiation Oncology, Harvard Medical School - Joint Center for Radiation Therapy, Boston, Massachusetts |
| 1991-2000 | Research Fellowship, Children's Hospital and Harvard Medical School, Boston, Massachusetts |
| 1989-1991 | Clinical Residency, Surgery, University of Massachusetts Medical Center, Worcester, Massachusetts |
Board Certifications
| 2000 | American Board of Radiation Oncology |
Experience & Service
Academic Appointments
Associate Professor, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2019
Associate Professor, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2011
Assistant Professor, Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2000 - 2008
Assistant Professor, Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2000 - 2008
Officer, Department of Surgical Research, Children's Hospital, Harvard University, Boston, MA, 1991 - 2000
Administrative Appointments/Responsibilities
Associate Medical Director, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present
Faculty liaison for the mid-level practitioners, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - Present
Institutional Animal Care and Use Committee, Children's Hospital, Boston, MA, 1998 - 2000
Other Appointments/Responsibilities
Adjunct Member, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, 2009 - Present
Consultantships, Genzyme, Boston, MA, 2001 - 2001
Consultantships, EntreMed, Rockville, MD, 2000 - 2000
Institutional Committee Activities
Member, Credentials Committee of the Medical Staff, 2023 - Present
Department representative, Faculty Appeals Committee, 2023 - Present
Liaison, Cancer Network, 2022 - Present
Thoracic Radiation Oncology representative, Virtual Second Opinion Working Group, 2022 - Present
Thoracic section faculty liaison, Radiation Oncology Quality and Safety Committee, 2021 - Present
Thoracic service champion for electron planning, New Procedure Committee, 2020 - Present
Member, Thoracic Access Work Group, 2020 - Present
Member, Medicare EHR Incentive Payment Program Physician Steering Committee, 2011 - Present
Member, Clinical Revenue Cycle Committee, 2010 - Present
Member, Faculty Senate Finance Committee, 2010 - Present
Senator, Faculty Senate, 2010 - Present
Member, Molecular Testing Evaluation Committee, 2010 - Present
Member, Clinical Research Committee II, 2004 - 2005
Member, Conflict of Interest Committee, 2004 - 2010
Honors & Awards
| 2000 | Physician Scientist Program, The University of Texas M. D. Anderson Cancer Center |
| 1996 | Anna Belsky Moranis Visiting Professorship of Medicine, New York University Medical Center |
Selected Publications
Peer-Reviewed Articles
- Ning, M, Odwuor, A, Chang, JY, Gandhi, S, Liao, Z, Lin, SH, Chen, A, Welsh, J, Nguyen, Q, O'Reilly, M, Chun, SG, Bronk, JK, Qian, DC, Lee, PP. Salvage Reirradiation with Proton Beam Therapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. Cancers 16(21), 2024. e-Pub 2024.
- Chung CV, Khan MS, Olanrewaju A, Pham M, Nguyen QT, Patel T, Das P, O'Reilly MS, Reed VK, Jhingran A, Simonds H, Ludmir EB, Hoffman KE, Naidoo K, Parkes J, Aggarwal A, Mayo LL, Shah SJ, Tang C, Beadle BM, Wetter J, Walker G, Hughes S, Mullassery V, Skett S, Thomas C, Zhang L, Nguyen S, Mumme RP, Douglas RJ, Baroudi H, Court LE. Knowledge-based planning for fully automated radiation therapy treatment planning of 10 different cancer sites. Radiother Oncol 202:110609, 2024. e-Pub 2024. PMID: 39486482.
- Ning MS, Odwuor A, Chang JY, Gandhi S, Liao Z, Lin SH, Chen A, Welsh JW, Nguyen QN, O'Reilly MS, Chun SG, Bronk J, Qian D, Lee P. Salvage Reirradiation with Proton Beam Therapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. Cancers (Basel) 16(21), 2024. e-Pub 2024. PMID: 39518028.
- Corrigan KL, Xu T, Sasaki Y, Lin R, Chen AB, Welsh JW, Lin SH, Chang JY, Ning MS, Gandhi S, O'Reilly MS, Gay CM, Altan M, Lu C, Cascone T, Koutroumpakis E, Sheshadri A, Zhang X, Liao L, Zhu XR, Heymach JV, Nguyen QN, Liao Z. Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma. Radiother Oncol 193:110121, 2024. e-Pub 2024. PMID: 38311031.
- Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Skoulidis F, Chang JY, Liao Z, Gomez DR, O'Reilly M, Heymach JV, Tsao AS, Lin SH. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer 174:112-117, 2022. e-Pub 2022. PMID: 36371941.
- Hui D, Puac V, Shelal Z, Dev R, Hanneman SK, Jennings K, Ma H, Urbauer DL, Shete S, Fossella F, Liao Z, Blumenschein G, Chang JY, O'Reilly M, Gandhi SJ, Tsao A, Mahler DA, Bruera E. Effect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial. Lancet Oncol 23(10):1321-1331, 2022. e-Pub 2022. PMID: 36087590.
- Lin SH, Lin HY, Verma V, Xu-Welliver M, Thall PF, Yao L, Kim PY, Gombos DS, Kawedia JD, Komaki R, Gomez DR, Nguyen QN, O'Reilly MS, Lu C, Fossella FV, Skoulidis F, Zhang J, Tsao AS, Heymach JV, Blumenschein GR. Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. Cancer Treat Res Commun 30:100514, 2022. e-Pub 2022. PMID: 35051703.
- Chang JY, Mehran RJ, Feng L, Verma V, Liao Z, Welsh JW, Lin SH, O'Reilly MS, Jeter MD, Balter PA, McRae SE, Berry D, Heymach JV, Roth JA. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol 22(10):1448-1457, 2021. e-Pub 2021. PMID: 34529930.
- Jing W, Liu Y, Zhu H, Welsh J, Gandhi S, Jeter M, Nguyen Q, Chen AB, O'Reilly M, Liao Z, Chang JY, Lee P, Lin SH. Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study. Clin Transl Radiat Oncol 28:54-61, 2021. e-Pub 2021. PMID: 33778173.
- Mesko S, Ning MS, Lakomy D, Verma V, Chang JY, O'Reilly MS, Jeter MD, Gandhi SJ, Lin SH, Nguyen QN, Liao Z, Welsh J, Chen AB, Hahn S, Gomez DR. Thoracic radiation oncology clinical trial accrual and reasons for non-enrollment: results of a large, prospective, multi-year analysis. Int J Radiat Oncol Biol Phys 107(5):897-908, 2020. e-Pub 2020. PMID: 32360653.
- Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol 15(2):248-257, 2020. e-Pub 2020. PMID: 31778797.
- Nguyen QN, Chun SG, Chow E, Komaki R, Liao Z, Zacharia R, Szeto BK, Welsh JW, Hahn SM, Fuller CD, Moon BS, Bird JE, Satcher R, Lin PP, Jeter M, O'Reilly MS, Lewis VO. Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial. JAMA Oncol 5(6):872-878, 2019. e-Pub 2019. PMID: 31021390.
- Brooks ED, Sun B, Feng L, Verma V, Zhao L, Gomez DR, Liao Z, Jeter M, O'Reilly M, Welsh JW, Nguyen QN, Erasmus JJ, Eapen G, Ahrar K, Antonoff MB, Hahn SM, Heymach JV, Rice DC, Chang JY. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. JAMA Netw Open 1(4):e181390, 2018. e-Pub 2018. PMID: 30646121.
- Liao Z, Lee JJ, Komaki R, Gomez DR, O'Reilly MS, Fossella FV, Blumenschein GR Jr, Heymach JV, Vaporciyan AA, Swisher SG, Allen PK, Choi NC, DeLaney TF, Hahn SM, Cox JD, Lu CS, Mohan R. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 36(18):1813-1822, 2018. e-Pub 2018. PMID: 29293386.
- Jeter MD, Gomez D, Nguyen QN, Komaki R, Zhang X, Zhu X, O'Reilly M, Fossella FV, Xu T, Wei X, Wang H, Yang W, Tsao A, Mohan R, Liao Z. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. Int J Radiat Oncol Biol Phys 100(3):730-737, 2018. e-Pub 2018. PMID: 29248169.
- Sun B, Brooks ED, Komaki RU, Liao Z, Jeter MD, McAleer MF, Allen PK, Balter PA, Welsh JD, O'Reilly MS, Gomez D, Hahn SM, Roth JA, Mehran RJ, Heymach JV, Chang JY. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. Cancer 123(16):3031-3039, 2017. e-Pub 2017. PMID: 28346656.
- Chang JY, Verma V, Li M, Zhang W, Komaki R, Lu C, Allen PK, Liao Z, Welsh J, Lin SH, Gomez D, Jeter M, O'Reilly M, Zhu RX, Zhang X, Li H, Mohan R, Heymach JV, Vaporciyan AA, Hahn S, Cox JD. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol 3(8):e172032, 2017. e-Pub 2017. PMID: 28727865.
- Brooks ED, Sun B, Zhao L, Komaki R, Liao Z, Jeter M, Welsh JW, O'Reilly MS, Gomez DR, Hahn SM, Heymach JV, Rice DC, Chang JY. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 98(4):900-907, 2017. e-Pub 2017. PMID: 28258887.
- Sun B, Brooks ED, Komaki R, Liao Z, Jeter M, McAleer M, Balter PA, Welsh JD, O'Reilly M, Gomez D, Hahn SM, Sepesi B, Rice DC, Heymach JV, Chang JY. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. J Thorac Oncol 12(6):983-992, 2017. e-Pub 2017. PMID: 28259750.
- Chang JY, Zhang W, Komaki R, Choi NC, Chan S, Gomez D, O'Reilly MS, Jeter M, Gillin M, Zhu X, Zhang X, Mohan R, Swisher S, Hahn S, Cox JD. Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. Radiother Oncol 122(2):274-280, 2017. e-Pub 2017. PMID: 28139305.
- Wang XS, Shi Q, Williams LA, Komaki R, Gomez DR, Lin SH, Chang JY, O'Reilly MS, Bokhari RH, Cox JD, Mohan R, Cleeland CS, Liao Z. Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. J Pain Symptom Manage 51(5):832-838, 2016. e-Pub 2016. PMID: 26891607.
- Xu T, Liao Z, O'Reilly MS, Levy LB, Welsh JW, Wang LE, Lin SH, Komaki R, Liu Z, Wei Q, Gomez DR. Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer. Radiother Oncol 113(3):379-384, 2014. e-Pub 2014. PMID: 25466375.
- Gomez DR, Gladish GW, Wei X, Kotamarti KR, Allen PK, Cox JD, O'Reilly MS, Erasmus JJ, Fossella FV, Komaki R. Prognostic Value of Positron Emission Tomography/Computed Tomography Findings in Limited-stage Small Cell Lung Cancer Before Chemoradiation Therapy. Am J Clin Oncol 37(1):77-80, 2014. e-Pub 2014. PMID: 23111360.
- Wang H, Liao Z, Zhuang Y, Xu T, Nguyen QN, Levy LB, O'Reilly MS, Gold KA, Gomez DR. Do Angiotensin-Converting Enzyme Inhibitors Reduce the Risk of Symptomatic Radiation Pneumonitis in Patients With Non-Small Cell Lung Cancer After Definitive Radiation Therapy? Analysis of a Single-Institution Database. Int J Radiat Oncol Biol Phys, 2013. e-Pub 2013. PMID: 24161424.
- Shirvani SM, Juloori A, Allen PK, Komaki R, Liao Z, Gomez D, O'Reilly MS, Welsh J, Papadimitrakopoulou V, Cox JD, Chang JY. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys 87(1):139-47, 2013. e-Pub 2013. PMID: 23920393.
- Skinner HD, McCurdy MR, Echeverria AE, Lin SH, Welsh JW, O'Reilly MS, Hofstetter WL, Ajani JA, Komaki R, Cox JD, Sandulache VC, Myers JN, Guerrero TM. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol 52(5):1002-9, 2013. e-Pub 2013. PMID: 22950385.
- Wang HM, Liao ZX, Komaki R, Welsh JW, O'Reilly MS, Chang JY, Zhuang Y, Levy LB, Lu C, Gomez DR. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol 24(5):1312-9, 2013. e-Pub 2013. PMID: 23300016.
- Isobe T, Onn A, Morgensztern D, Jacoby JJ, Wu W, Shintani T, Itasaka S, Shibuya K, Koo PJ, O'Reilly MS, Herbst RS. Evaluation of Novel Orthotopic Nude Mouse Models for Human Small-Cell Lung Cancer. J Thorac Oncol 8(2):140-6, 2013. e-Pub 2013. PMID: 23328546.
- Saintigny P, Massarelli E, Lin S, Ahn YH, Chen Y, Goswami S, Erez B, O'Reilly MS, Liu D, Lee JJ, Zhang L, Ping Y, Behrens C, Solis Soto LM, Heymach JV, Kim ES, Herbst RS, Lippman SM, Wistuba II, Hong WK, Kurie JM, Koo JS. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res 73(2):571-82, 2013. e-Pub 2013. PMID: 23204236.
- Baird BN, Schliekelman MJ, Ahn YH, Chen Y, Roybal JD, Gill BJ, Mishra DK, Erez B, O'Reilly MS, Yang Y, Patel M, Liu X, Thilaganathan N, Larina IV, Dickinson ME, West JL, Gibbons DL, Liu DD, Kim MP, Hicks JM, Wistuba II, Hanash SM, Kurie JM. Fibulin-2 is a driver of malignant progression in lung adenocarcinoma. PLoS One 8(6):e67054, 2013. e-Pub 2013. PMID: 23785517.
- Xu T, Wei Q, Lopez Guerra JL, Wang LE, Liu Z, Gomez D, O'Reilly MS, Lin SH, Zhuang Y, Levy LB, Mohan R, Zhou H, Liao Z. HSPB1 gene polymorphisms predict risk of mortality for US patients after radio(chemo)therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 84(2):e229-35, 2012. e-Pub 2012. PMID: 22608953.
- Yin M, Liao Z, Yuan X, Guan X, O'Reilly MS, Welsh J, Wang LE, Wei Q. Polymorphisms of the VEGF Gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy. Cancer Sci 103(5):945-50, 2012. e-Pub 2012. PMID: 22320189.
- Takahashi O, Komaki R, Smith PD, Jürgensmeier JM, Ryan A, Bekele BN, Wistuba II, Jacoby JJ, Korshunova MV, Biernacka A, Erez B, Hosho K, Herbst RS, O'Reilly MS. Combined MEK and VEGFR Inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clin Cancer Res 18(6):1641-54, 2012. e-Pub 2012. PMID: 22275507.
- Yin M, Liao Z, Liu Z, Wang LE, O'Reilly MS, Gomez D, Li M, Komaki R, Wei Q. Genetic variants of the nonhomologous end joining gene LIG4 and severe radiation pneumonitis in nonsmall cell lung cancer patients treated with definitive radiotherapy. Cancer 118(2):528-35, 2012. e-Pub 2012. PMID: 21717429.
- Komaki R, Wei X, Allen PK, Liao Z, Milas L, Cox JD, O'Reilly MS, Chang JY, McAleer MF, Jeter M, Blumenschein GR, Kies MS. Phase I study of celecoxib with concurrent irinotecan, cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Front Oncol 1:1-7, 2011. e-Pub 2011. PMID: 22649768.
- Jacoby JJ, Erez B, Korshunova MV, Williams RR, Furutani K, Takahashi O, Kirkpatrick L, Lippman SM, Powis G, O'Reilly MS, Herbst RS. Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice. J Thorac Oncol 5(7):940-9, 2010. e-Pub 2010. PMID: 20512076.
- Guan X, Yin M, Wei Q, Zhao H, Liu Z, Wang LE, Yuan X, O'Reilly MS, Komaki R, Liao Z. Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer 10:431, 2010. e-Pub 2010. PMID: 20712888.
- McGovern SL, Liao Z, Bucci MK, McAleer MF, Jeter MD, Chang JY, O'Reilly MS, Cox JD, Allen PK, Komaki R. Is sex associated with the outcome of patients treated with radiation for nonsmall cell lung cancer?. Cancer 115:3233-42, 2009. e-Pub 2009. PMID: 19472405.
- Shibuya K, Komaki R, Shintani T, Itasaka S, Ryan A, Jürgensmeier JM, Milas L, Ang K, Herbst RS, O'Reilly MS. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 69(5):1534-43, 2007. e-Pub 2007. PMID: 17889445.
- Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, Herbst RS, O'Reilly MS. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 6:471-483, 2007. e-Pub 2007. PMID: 17308046.
- Itasaka S, Komaki R, Herbst RS, Shibuya K, Shintani T, Hunter NR, Onn A, Bucana CD, Milas L, Ang KK, O'Reilly MS. Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice. Int J Radiat Oncol Biol Phys 67:870-8, 2007. e-Pub 2007. PMID: 17293237.
- Wu W, O'Reilly MS, Langley RR, Tsan RZ, Baker CH, Bekele N, Tang XM, Onn A, Fidler IJ, Herbst RS. Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. Mol Cancer Ther 6:2652-2663, 2007. e-Pub 2007. PMID: 17913856.
- Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PW, Charnsangavej C, Delclos ME, O'Reilly MS, Lee JE, Wolff RA. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 24:1145-1151, 2006. e-Pub 2006. PMID: 16505434.
- Marcus K, Johnson M, Adam RM, O'Reilly MS, Donovan M, Atala A, Freeman MR, Soker S. Tumor cell-associated neuropilin-1 and vascular endothelial growth factor expression as determinants of tumor growth in neuroblastoma. Neuropathology 25:178-187, 2005. e-Pub 2005. PMID: 16193833.
- Onn A, Correa AM, Gilcrease M, Isobe T, Massarelli E, Bucana CD, O'Reilly MS, Hong WK, Fidler IJ, Putnam JB, Herbst RS. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res 10:136-143, 2004. e-Pub 2004. PMID: 14734462.
- Onn A, Isobe T, Wu W, Itasaka S, Shintani T, Shibuya K, Kenji Y, O'Reilly MS, Fidler IJ, Herbst RS. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer. Clin Cancer Res 10:8613-8619, 2004. e-Pub 2004. PMID: 15623645.
- Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O'Reilly MS, Abbruzzese JL, McConkey DJ. Quantitative analysis of biomarkers defines an optimal biological dose for recombinant human endostatin in primary human tumors. Clin Cancer Res 10:33-42, 2004. e-Pub 2004. PMID: 14734449.
- Raut CP, Takamori RK, Davis DW, Sweeney-Gotsch B, O'Reilly MS, McConkey DJ. Direct effects of recombinant human endostatin on tumor cell IL-8 production are associated with increased endothelial cell apoptosis in an orthotopic model of human pancreatic cancer. Cancer Biol Ther 3:679-687, 2004. e-Pub 2004. PMID: 15197351.
- Chandra A, Liu H, Tucker SL, Liao ZX, Stevens C, Chang JY, Jeter M, O'Reilly MS, Mohan R, Cox JD, Komaki R, Guerrero T. IMRT reduces lung irradiation in distal esophageal cancer 3D CRT. Int J Radiat Oncol Biol Phys 57:S384-385, 2003. e-Pub 2003.
- Greene AK, Wiener S, Puder M, Yoshida A, Shi B, Perez-Atayde AR, Efstathiou JA, Holmgren L, Adamis AP, Rupnick M, Folkman J, O'Reilly MS. Endothelial-directed hepatic regeneration after partial hepatectomy. Ann Surg 237:530-535, 2003. e-Pub 2003. PMID: 12677150.
- Camphausen K, Moses MA, Menard C, Sproull M, Beecken WD, Folkman J, O'Reilly MS. Radiation abscopal antitumor effect is mediated through p53. Cancer Res 63:1990-1993, 2003. e-Pub 2003. PMID: 12702593.
- Onn A, Isobe T, Itasaka S, Wu W, O'Reilly MS, Ki Hong W, Fidler IJ, Herbst RS. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res 9:5532-5539, 2003. e-Pub 2003. PMID: 14654533.
- Herbst RS, Mullani NA, Davis DW, Hess KR, McConkey DJ, Charnsangavej C, O'Reilly MS, Kim HW, Baker C, Roach J, Ellis LM, Rashid A, Pluda J, Bucana C, Madden TL, Tran HT, Abbruzzese JL. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 20:3804-3814, 2002. e-Pub 2002. PMID: 12228200.
- Herbst RS, Hess KR, Tran HT, Tseng JE, Mullani NA, Charnsangavej C, Madden T, Davis DW, McConkey DJ, O'Reilly MS, Ellis LM, Pluda J, Hong WK, Abbruzzese JL. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 20:3792-3803, 2002. e-Pub 2002. PMID: 12228199.
- Ambati BK, Joussen AM, Ambati J, Moromizato Y, Guha C, Javaherian K, Gillies S, O'Reilly MS, Adamis AP. Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol 120:1063-1068, 2002. e-Pub 2002. PMID: 12149060.
- Lewis VO, O'Reilly MS, Gehrmann M, Llinas M, Schaller J, Weissbach L. Inhibition of tumor growth by plasminogen-related protein-B. Anticancer Res 21:2287-2291, 2001. e-Pub 2001. PMID: 11724284.
- Camphausen K, Moses MA, Beecken WD, Khan MK, Folkman J, O'Reilly MS. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 61:2207-2211, 2001. e-Pub 2001. PMID: 11280788.
- Kisker O, Onizuka S, Banyard J, Komiyama T, Becker CM, Achilles EG, Barnes CM, O'Reilly MS, Folkman J, Pirie-Shepherd SR. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. Cancer Res 61:7298-7304, 2001. e-Pub 2001. PMID: 11585769.
- Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886, 2000. e-Pub 2000. PMID: 10766175.
- O'Reilly MS, Wiederschain D, Stetler-Stevenson WG, Folkman J, Moses MA. Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 274:29568-29571, 1999. e-Pub 1999. PMID: 10506224.
- O'Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 285:1926-1928, 1999. e-Pub 1999. PMID: 10489375.
- Sim BK, Fogler WE, Zhou XH, Liang H, Madsen JW, Luu K, O'Reilly MS, Tomaszewski JE, Fortier AH. Zinc ligand-disrupted recombinant human Endostatin: potent inhibition of tumor growth, safety and pharmacokinetic profile. Angiogenesis 3:41-51, 1999. e-Pub 1999. PMID: 14517443.
- Cao Y, O'Reilly MS, Marshall B, Flynn E, Ji RW, Folkman J. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 101:1055-1063, 1998. e-Pub 1998. PMID: 9486976.
- Claesson-Welsh, L, Welsh, M, Ito, N, Anand-Apte, B, Soker, S, Zetter, B, O'Reilly MS, Folkman, J. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independent of the integrin-binding motif RGD. Proc Natl Acad Sci, USA 95:5579-5583, 1998. e-Pub 1998.
- Boehm T, O'Reilly MS, Keough K, Shiloach J, Shapiro R, Folkman J. Zinc-binding of endostatin is essential for its antiangiogenic activity. Biochem Biophys Res Commun 252:190-194, 1998. e-Pub 1998. PMID: 9813168.
- Sim BK, O'Reilly MS, Liang H, Fortier AH, He W, Madsen JW, Lapcevich R, Nacy CA. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 57:1329-1334, 1997. e-Pub 1997. PMID: 9102221.
- O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285, 1997. e-Pub 1997. PMID: 9008168.
- Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390:404-407, 1997. e-Pub 1997. PMID: 9389480.
- Wu Z, O'Reilly MS, Folkman J, Shing Y. Suppression of tumor growth with recombinant murine angiostatin. Biochem Biophys Res Commun 236:651-654, 1997. e-Pub 1997. PMID: 9245707.
- Parangi, S, O'Reilly MS, Christofori, G, Holmgren, L, Grosfeld, J, Folkman, J, Hanahan, D. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 93:2002-2007, 1996. e-Pub 1996.
- Cao Y, Ji RW, Davidson D, Schaller J, Marti D, Sohndel S, McCance SG, O'Reilly MS, Llinas M, Folkman J. Kringle domains of human angiostatin. Characterization of the anti-proliferative activity on endothelial cells. J Biol Chem 271:29461-29467, 1996. e-Pub 1996. PMID: 8910613.
- O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 2:689-692, 1996. e-Pub 1996. PMID: 8640562.
- Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581-586, 1995. e-Pub 1995. PMID: 7538593.
- Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149-53, 1995. e-Pub 1995. PMID: 7585012.
- O'Reilly MS, Brem H, Folkman J. Treatment of murine hemangioendotheliomas with the angiogenesis inhibitor AGM-1470. J Pediatr Surg 30:325-329; discussion 329-330, 1995. e-Pub 1995. PMID: 7738759.
- O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79:315-328, 1994. e-Pub 1994. PMID: 7525077.
- Miller JW, Adamis AP, Shima DT, D'Amore PA, Moulton RS, O'Reilly MS, Folkman J, Dvorak HF, Brown LF, Berse B, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 145:574-84, 1994. e-Pub 1994. PMID: 7521577.
- O'Reilly MS, Rosenthal, R, Sage, EH, Smith, S, Holmgren, L, Moses, M, Shing, Y, Folkman, J. The suppression of tumor metastases by a primary tumor. Surgical Forum 44:474-476, 1993. e-Pub 1993.
Invited Articles
- O'Reilly MS. The interaction of radiation therapy and antiangiogenic therapy. Cancer J 14(4):207-213, 2008. e-Pub 2008. PMID: 18677126.
- O'Reilly MS. Antiangiogenic Antithrombin. Semin Thromb Hemost 33(7):660-666, 2007. e-Pub 2007. PMID: 18000792.
- Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ. ZD6474: an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 16:239-249, 2007. e-Pub 2007.
- O'Reilly MS. Radiation combined with antiangiogenic and antivascular agents. Semin Radiat Oncol 16(1):45-50, 2006. e-Pub 2006. PMID: 16378906.
- McDonald MD, Teicher BA, Stetler-Stevenson W, Ng SS, Figg WD, Folkman J, Hanahan D, Auerbach R, O'Reilly MS, Herbst R, Cheresh D, Gordon M, Eggermont A, Libutti SK. Report from the Society for Biological Therapy and Vascular Biology faculty of the NCI workshop on Angiogenesis Mentoring. J Immunotherapy 27:161-175, 2004. e-Pub 2004.
- O'Reilly MS. Anti-vascular endothelial growth factor therapy in colon cancer. Principles & Practice of Oncology Updates 18:1-15, 2004. e-Pub 2004.
- Herbst RS, O'Reilly MS. The rationale and potential of combining novel biologic therapies with radiotherapy: focus on non-small cell lung cancer. Semin Oncol 30(4 Suppl 9):113-123, 2003. e-Pub 2003. PMID: 12908142.
- Moses MA, O'Reilly MS. Regulation of angiostatin mobilization by tumor-derived matrix metalloproteinase-2. Methods Mol Med 74:375-390, 2003. e-Pub 2003. PMID: 12415709.
- O'Reilly MS. Therapeutic strategies using inhibitors of angiogenesis. Methods Mol Biol 223:599-634, 2003. e-Pub 2003. PMID: 12777753.
- O'Reilly MS. The combination of antiangiogenic therapy with other modalities. Cancer J 8 Suppl 1:S89-99, 2002. e-Pub 2002. PMID: 12075706.
- O'Reilly MS. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. EXS 79:273-294, 1997. e-Pub 1997. PMID: 9002223.
- O'Reilly MS. The preclinical evaluation of angiogenesis inhibitors. Invest New Drugs 15:5-13, 1997. e-Pub 1997. PMID: 9195285.
- O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Cao Y, Moses M, Lane WS, Sage EH, Folkman J. Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol 59:471-482, 1994. e-Pub 1994. PMID: 7587101.
Other Articles
- Samson P, Ning MS, Shaverdian N, Shepherd AF, Gomez DR, McGinnis GJ, Nitsch PL, Chmura S, O'Reilly MS, Lee P, Chang JY, Robinson C, Lin SH Clinical and Radiographic Presentations of COVID-19 among Patients Receiving Radiation Therapy for Thoracic Malignancies. Adv Radiat Oncol 5(4):700-704, 2020. PMID: 32395673.
- McGinnis GJ, Ning MS, Nitsch PL, O'Reilly MS, McAleer MF, Koong AC, Chang JY Rapid Detection of Asymptomatic Coronavirus Disease 2019 by Computed Tomography Image Guidance for Stereotactic Ablative Radiotherapy. J Thorac Oncol 15(6):1085-1087, 2020. PMID: 32311499.
- Herbst RS, Heymach JV, O'Reilly MS, Onn A, Ryan AJ Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 16(2):239-49, 2007. PMID: 17243944.
- O'Reilly MS Antiangiogenesis and vascular endothelial growth factor/vascular endothelial growth factor receptor targeting as part of a combined-modality approach to the treatment of cancer. Int J Radiat Oncol Biol Phys 69:S64-6, 2007. PMID: 17848299.
Editorials
- O'Reilly MS. Vessel maneuvers: vaccine targets tumor vasculature. Nat Med 8:1352-1353, 2002. PMID: 12457172.
- O'Reilly, MS. Targeting multiple biological pathways as a strategy to improve the treatment of cancer. Clin Cancer Res 8:3309-3310, 2002. PMID: 12429615.
Book Chapters
- Ang, KK, O'Reilly MS, Meyn, RE, Milas, L. Principles of combining radiation therapy with molecular therapeutics. In: Radiation Oncology 9th Edition. Elsevier, 118-140, 2010.
- O'Reilly MS, Fidler IJ. The Development of Antiangiogenic Agents for the Clinic. In: Progress in Oncology 2002. Jones and Bartlett Publishers, Inc, 129-157, 2003.
- O'Reilly MS. Therapeutic Strategies Using Inhibitors of Angiogenesis. In: Tumor Suppressor Genes Volume 2: Regulation, Function, and Medicinal Applications. Humana Press, Inc, 599-633, 2003.
- O'Reilly MS. Antiangiogenesis: basic principles and preclinical models. In: Principles and Practice of the Biologic Therapy of Cancer. Lippincott Williams & Wilkins, 827-843, 2000.
- O'Reilly MS. Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth. In: Regulation of Angiogenesis. Birkhauser Verlag, 273-294, 1997.
Selected Presentations & Talks
National Presentations
- 2013. Invited faculty and session chair. Invited. Thirteenth Annual Targeted Therapies for the Treatment of Lung Cancer Conference. Santa Monica, CA, US.
- 2012. Invited faculty. Invited. Twelth Annual Targeted Therapies for the Treatment of Lung Cancer Conference. Santa Monica, CA, US.
- 2011. Invited faculty. Conference. American Radium Society 93rd Annual Meeting. Palm Beach, FL, US.
- 2011. Invited faculty. Invited. Eleventh Annual Targeted Therapies for the Treatment of Lung Cancer Conference. Santa Monica, CA, US.
- 2010. Invited faculty. Invited. Tenth Annual Targeted Therapies for the Treatment of Lung Cancer Conference. Santa Monica, CA, US.
- 2009. Invited faculty. Invited. GlaxoSmithKline Introduction to Oncologic Product Development. Upper Providence, PA, US.
- 2009. Invited faculty. Conference. GlaxoSmithKline Introduction to Oncology Course. Durham, NC, US.
- 2009. Minisymposium chair. Invited. AACR Annual Meeting. Denver, CO, US.
- 2009. Invited faculty. Invited. Ninth Annual Targeted Therapies for the Treatment of Lung Cancer Conference. Santa Monica, CA, US.
- 2008. Invited participant. Invited. 2008 AstraZeneca Scientific Cross Alliance Symposium. Waltham, MA, US.
- 2008. Invited speaker. Invited. Judah Folkman Tribute and Scientific Symposium. Boston, MA, US.
- 2008. Invited faculty. Invited. GlaxoSmithKline Introduction to Oncology Course. Philadelphia, PA, US.
- 2008. Minisymposium chair. Invited. AACR Annual Meeting. San Diego, CA, US.
- 2008. Invited faculty. Invited. Eighth Annual Targeted Therapies for the Treatment of Lung Cancer Conference. Santa Monica, CA, US.
- 2007. Invited participant. Invited. Oncology Phase I Investigator AstraZeneca Summit. San Francisco, CA, US.
- 2007. Invited faculty. Invited. GlaxoSmithKline Introduction to Oncology Course. Philadelphia, PA, US.
- 2007. Invited faculty. Invited. Seventh Annual Targeted Therapies for the Treatment of Lung Cancer Conference. Santa Monica, CA, US.
- 2007. Invited faculty. Invited. Multidisciplinary Head and Neck Cancer Symposium. Rancho Mirage, CA, US.
- 2006. Invited faculty. Invited. Lung Cancer Scientific Symposium. Waltham, MA, US.
- 2006. Invited participant. Invited. AZD5180 Advisory Board for AstraZeneca. Waltham, MA, US.
- 2006. Invited faculty. Invited. 14th Annual Radiation Workshop at Round Top. Round Top, TX, US.
- 2006. Invited faculty. Invited. American College of Radiation Oncology Annual Meeting. Orlando, FL, US.
- 2006. Invited faculty. Invited. Sixth Annual Targeted Therapies for the Treatment of Lung Cancer Conference. Santa Monica, CA, US.
- 2005. Invited participant. Invited. AZD2171 and Zactima Advisory Board for AstraZenca. Waltham, MA, US.
- 2005. Invited faculty. Invited. 3rd Annual Atlanta Lung Cancer Symposium,. Atlanta, GA, US.
- 2005. Invited participant. Invited. Advisory Board for AstraZeneca. Anaheim, CA, US.
- 2005. Invited participant. Invited. Iressa Advisory Board for AstraZeneca. Santa Monica, CA, US.
- 2005. Invited participant. Invited. AZD2171 and ZD6474 Advisory Board for AstraZeneca. Anaheim, CA, US.
- 2005. Invited participant. Invited. Advisory Board for Astrazeneca. Santa Monica, CA, US.
- 2005. Invited faculty. Invited. 5th Annual Targeted Therapies for the Treatment of Lung Cancer. Steamboat Springs, CO, US.
- 2004. Invited faculty. Invited. Integrating Novel Agents with Radiotherapy in the Treatment of Solid Tumors Conference. Lake Tahoe, NV, US.
- 2004. Invited faculty. Invited. Targeted Therapies for the Treatment of Lung Cancer Investigators’ Meeting. San Diego, CA, US.
- 2004. Invited panelist. Invited. Fragmin Oncology Scientific Expert Panel Meeting. New York, NY, US.
- 2003. Invited faculty. Invited. Iressa Opinion Leader Summit. Boston, MA, US.
- 2003. Invited faculty. Invited. Lung Cancer Strategy Meeting. Aspen, CO, US.
- 2002. Invited faculty. Invited. Duke Oncology Consortium Cancer, Angiogenesis, & Thrombosis Symposium. Asheville, NC, US.
- 2002. Invited faculty. Invited. 27th Society of Cardiovascular & Inverventional Radiology Annual Scientific Meeting. Baltimore, MD, US.
- 2002. Invited faculty. Invited. Annual Meeting of the American Radium Society. San Juan, PR, US.
- 2002. Invited participant. Invited. Banbury Center Meeting, Endostatin: Structure, Function and Applications. Cold Spring Harbor, NY, US.
- 2002. Invited faculty. Invited. Second Annual Opinion Leader Summit: Targeted Therapies in The Treatment of Lung Cancer. Scottsdale, AZ, US.
- 2002. Invited participant. Invited. Johnson & Johnson sponsored Cancer Workshop on The Genomic/Proteomic Revolution. Naples, FL, US.
- 2002. Keynote speaker. Invited. 1st Annual Hackensack University Medical Center Lung Symposium. Hackensack, NJ, US.
- 2001. Invited faculty. Invited. 24th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, US.
- 2001. Invited faculty and panelist. Invited. ASTRO Annual Meeting Lung Cancer Panel. San Francisco, CA, US.
- 2001. Invited faculty. Invited. 3rd National Oncology Forum. Washington, US.
- 2001. Invited faculty. Invited. Third Annual Lynn Sage Breast Cancer Symposium. Chicago, IL, US.
- 2001. Special lecturer. Invited. Annual meeting of the Korean Cancer Society. Seoul.
- 2001. Invited faculty. Invited. Safety Considerations in Cardiovascular Gene Transfer Clinical Research. Irving, TX, US.
- 2001. Invited faculty. Invited. Advisory meeting on LY317615 for Eli Lilly and Company. Irving, TX, US.
- 2000. Invited faculty and panelist. Invited. NIH 3rd Gene Transfer Clinical Research Safety Symposium on Safety Considerations in Cardiovascular Gene Transfer Clinical Research. Bethesda, MD, US.
- 2000. Invited faculty. Invited. Society for Urologic Research 2000 Fall Symposium. Fort Myers, FL, US.
- 2000. Keynote speaker. Invited. Woods Hole Conference on Lung Cell Biology. Woods Hole, MA, US.
- 2000. Invited faculty. Invited. 2nd Annual National Oncology Forum. Chicago, IL, US.
- 2000. Invited faculty. Invited. Chemoradiation symposium. Yosemite, CA, US.
- 2000. Invited faculty. Invited. Era of Hope Department of Defense Breast Cancer Research Meeting. Atlanta, GA, US.
- 2000. Invited faculty. Invited. Celgene CME Dinner Series. Pittsburgh, PA, US.
- 2000. Keynote speaker. Invited. Engineering Foundation Cell Culture Engineering VII Conference. Santa Fe, NM, US.
- 1999. Invited faculty. Invited. Chemotherapy Foundation Symposium XVII. New York, NY, US.
- 1999. Invited faculty. Invited. National Oncology Forum. Chicago, IL, US.
- 1999. Invited faculty. Invited. 21st Biennial Cornea Research Conference. Boston, MA, US.
- 1999. Invited participant. Invited. NCI Translational Research in Radiation Oncology Workshop. Washington, DC, US.
- 1999. Keynote speaker. Invited. Collaborative Care in Radiation Oncology Symposium. Boston, MA, US.
- 1999. Invited faculty. Invited. Controlled Release Society Cancer Research Seminar Series. Boston, MA, US.
- 1999. Invited faculty. Invited. Swedish Medical Center Annual Cancer Conference. Seattle, WA, US.
- 1999. Invited faculty. Invited. Annual Meeting of the American Thoracic Society. San Diego, CA, US.
- 1999. Keynote speaker. Invited. Annual meeting of The American Radium Society. Honolulu, HI, US.
- 1999. Invited faculty. Invited. National Eye Institute Laboratory Seminar Series. Bethesda, MD, US.
- 1999. Invited faculty. Invited. Holland Labs of the American Red Cross Cancer Symposium. Rockville, MD, US.
- 1999. Invited faculty. Invited. Thoracic Malignancies: Prevention, Early Diagnosis & Treatment. Iowa City, IA, US.
- 1999. Invited faculty. Invited. 88th Annual USCAP Meeting for Molecular Pathology. San Francisco, CA, US.
- 1998. Invited faculty. Invited. AACR New approaches in the prevention and cure of prostate cancer conference. Indian Wells, CA, US.
- 1998. Keynote Speaker. Invited. Massachusetts Society of Clinical Oncology Annual Meeting. Dedham, MA, US.
- 1998. Keynote speaker. Invited. Anti-cancer Proteins and Drugs Conference of the New York Academy of Sciences. New York, NY, US.
- 1998. Keynote speaker. Invited. 4th Annual Fall Education Conference of the Pennsylvania Oncology Hematology Manager’s Society. Hershey, PA, US.
- 1998. Invited faculty. Invited. Insights into the Molecular Genetics of Cancer Gordon Research Conference. New London, NH, US.
- 1998. Invited faculty. Invited. RTOG Annual Meeting. Washington, DC, US.
- 1998. Keynote Speaker. Invited. NABTT-Moffitt Meeting on Angiogenesis and Brain Tumor Therapy. Tampa, FL, US.
- 1998. Invited faculty. Invited. IBC Angiogenesis Conference. Boston, MA, US.
- 1998. Invited faculty. Invited. 3rd Annual Santa Barbara Workshop. Santa Barbara, CA, US.
- 1997. Invited faculty. Invited. Scripps Clinic 15th Clinical Hematology and Oncology Meeting. La Jolla, CA, US.
- 1996. Invited faculty. Invited. Angiogenesis Retreat, Parke-Davis. Ann Arbor, MI, US.
- 1996. Invited faculty. Invited. Angiogenesis: Basic Biology and Clinical Implications NCI Conference. Bethesda, MD, US.
- 1996. Invited faculty. Invited. Keystone Symposium on Cardiovascular Biology. Keystone, CO, US.
- 1996. Invited faculty. Invited. Thrombolysis Gordon Research Conference. Ventura, CA, US.
- 1996. Invited faculty. Invited. U.S. Japan Cooperative Research Program. Bethesda, MD, US.
- 1995. Invited faculty. Invited. Chemotherapy Foundation Symposium XIII. New York, NY, US.
- 1995. Invited faculty. Invited. Gordon Conference on Angiogenesis and Microcirculation. Newport, RI, US.
- 1995. Invited faculty. Invited. 3rd Growth Control in CNS Tumors Angiogenesis Symposium. Boston, MA, US.
- 1995. Invited faculty. Invited. CHI New Cancer Strategies: Angiogenesis Antagonists. Washington, DC, US.
- 1995. Invited faculty. Invited. Semi-Annual POG Meeting. St. Petersburg, FL, US.
International Presentations
- 2013. Invited faculty. Invited. MD Anderson Radiation Oncology/Gilbert H. Fletcher Society 37th Annual Scientific Meeting. Kyoto, JP.
- 2013. Invited faculty. Invited. MDACC-Kyoto University Symposium. Kyoto, JP.
- 2012. Invited reviewer and faculty. Invited. Cold Spring Harbor Asia, CN.
- 2011. Invited faculty. Invited. 12th International Lung Cancer Congress. Carlsbad, US.
- 2010. Invited faculty. Invited. 11th International Lung Cancer Congress. Rahco Palos Verdes, US.
- 2010. Invited participant. Invited. 2010 AstraZeneca Scientific Cross Alliance Symposium. Manchester, GB.
- 2009. Invited speaker. Invited. Kyoto University Cancer Conference. Kyoto, JP.
- 2009. Invited speaker. Invited. Tokyo Medical and Dental University Summer International Symposium. Tokyo, JP.
- 2009. Scientific Discussant. Invited. ASCO Annual Meeting. Orlando, US.
- 2008. Invited faculty and session chair. Invited. IASLC ESMO 1st European Lung Cancer Conference. Geneva, CH.
- 2007. Keynote speaker. Invited. IBC 5th International Anti-angiogenesis Conference. Boston, US.
- 2007. Invited speaker. Invited. Cancer Therapeutics: The Road Ahead Capri Science Conference. Capri, IT.
- 2007. Invited faculty. Invited. The 100th Anniversary of Tohoku University, The 5th Japan-US Cancer Therapy Symposium & The 5th S. Takahashi Memorial International Joint Symposium. Sendai, JP.
- 2007. Invited speaker. Invited. 12th IASLC World Conference on Lung Cancer. Seoul.
- 2006. Invited faculty. Invited. Fourth International Symposium on Malignancies of the Chest, Head, and Neck. Chicago, US.
- 2006. Invited faculty. Invited. AACR International Conference: Molecular Diagnostics in Cancer Therapeutic Development. Chicago, US.
- 2006. Invited faculty and session chair. Invited. Seventh International Lung Cancer Congress. Maui, US.
- 2006. Invited faculty. Invited. Combining Targeted Therapies with Radiation RTOG Meeting. Toronto, CA.
- 2006. Keynote speaker. Invited. Annual Meeting of the Japanese Surgical Society. Tokyo, JP.
- 2005. Invited faculty. Invited. Brazilian Cancer Society and ASCO Oncology Meeting. Rio de Janeiro, BR.
- 2005. Keynote speaker. Invited. Sixth International Lung Cancer Congress. Kauai, US.
- 2004. Keynote speaker. Invited. Global Trends in Cancer Research Conference. Tokyo, JP.
- 2004. Invited faculty. Invited. Biotherapy Development Association First Alpine Summit. Innsbruck, AT.
- 2004. Invited faculty. Invited. International Congress of Anti-Cancer Therapies. Paris, FR.
- 2003. Invited faculty. Invited. Canadian Cardiovascular Congress Angiogenesis Workshop. Toronto, CA.
- 2003. Keynote speaker. Invited. International Conference on Cancer Therapy. Kanazawa, JP.
- 2003. Invited faculty. Invited. Targeted Therapies for Head and Neck Cancer Meeting. San Juan, PR.
- 2002. Invited faculty. Invited. 1st International Targeted Therapies Congress. Washington, US.
- 2002. Invited faculty. Invited. The Future of Breast Cancer: An International Breast Cancer Congress. Paradise Island, BS.
- 2002. Invited faculty. Invited. 6th International Wolfsberg Meeting on Molecular Radiation Biology/Oncology. Ermatingen, CH.
- 2002. Special lecturer. Invited. Karolinska Institute Translational Cancer Research Symposium. Stockholm, SE.
- 2001. Keynote speaker. Invited. Symposium of the German and Austrian Societies of Hematology and Oncology. Mannheim, DE.
- 2001. Invited faculty. Invited. 3rd Annual Institute for International Research Angiogenesis Meeting. Boston, US.
- 2001. Invited faculty. Invited. 48th Annual meeting of the Society of Nuclear Medicine. Toronto, CA.
- 2001. Invited discussant. Invited. ASCO Annual Meeting Integrated Symposium. San Francisco, US.
- 2001. Invited faculty. Invited. American Association of Neurological Surgery Annual Meeting. Toronto, CA.
- 2000. Invited faculty. Invited. International Chemical Congress of the Pacific Basin Symposium on Natural Products Chemistry. Honolulu, US.
- 2000. Plenary speaker and commentator. Invited. 2nd Roche International Symposium on Cancer Research. Tokyo, JP.
- 2000. Keynote speaker. Invited. American Society for Bone and Mineral Research Annual Meeting and Molecular Biology and Pathology of Bone Working Group Symposium. Toronto, CA.
- 2000. Invited faculty. Invited. Joint Scientific Conference of the Canadian Society for Transfusion Medicine, the Canadian Blood Services, and Hema-Quebec. Quebec City, CA.
- 2000. Invited faculty. Invited. International Symposium on Angiogenesis in Oncology and Hematology. Muenster, DE.
- 2000. Keynote speaker. Invited. 3rd Fukuoka International Symposium on Medical Science. Fukuoka, JP.
- 1999. Keynote speaker. Invited. Medicine for the Millennium Conference. St. Georges, GD.
- 1999. Keynote speaker. Invited. BTDG/EORTC 5th International Symposium Biological Therapy of Cancer. Munich, DE.
- 1999. Invited faculty. Invited. International Conference on Prostate Cancer Research. Iowa City, US.
- 1999. Keynote speaker. Invited. Japanese Endocrine Society Annual Meeting. Yokohama, JP.
- 1999. Invited faculty. Invited. 14th International Conference on Oral and Maxillofacial Surgery. Washington, US.
- 1999. Invited faculty. Invited. 1st International Symposium on Antiangiogenic Agents. Irving, US.
- 1998. Keynote speaker. Invited. 3rd Annual Shizuoka Forum on Health and Longevity. Shizuoka, JP.
- 1998. Invited faculty. Invited. 7th International Congress of the Metastasis Research Society. San Diego, US.
- 1998. Keynote speaker. Invited. Vascular Biology and ECM International Symposium. Tegernsee, DE.
- 1998. Invited faculty. Invited. 4th European Conference on Gene Therapy of Cancer. Milan, IT.
- 1998. Invited faculty. Invited. NATO ASI Conference. Athens, GR.
- 1998. Keynote Speaker. Invited. CGGH Spring Symposium of the Japanese Biochemical Safety. Hiroshima, JP.
- 1998. Invited faculty. Invited. American Thoracic Society International Conference. Chicago, US.
- 1997. Invited faculty. Invited. New Strategies for Cancer Detection and Therapy. Melbourne, AU.
- 1997. Invited faculty. Invited. Philippe Laudat Conference on Biology and Physiopathology of Angiogenesis. Aix-les-bains, FR.
- 1997. Invited faculty. Invited. International Symposium on Cellular Endocrinology. Lake Placid, US.
- 1995. Invited faculty. Invited. 3rd Meeting of the European Working Group of Human Gene Transfer and Therapy. Barcelona, ES.
Formal Peers
- 2009. International Symposium summer course lecturer. Visiting. Tokyo Medical and Dental University. Tokyo, JP.
- 2008. Norman Nigro Research Lectureship. Visiting. The American Society of Colon and Rectal Surgeons. Boston, MA, US.
- 2007. Special Seminar for the Department of Radiation Oncology. Invited. Kyoto University. Kyoto, JP.
- 2006. Ochsner Basic Science in Clinical Medicine Lecture Series. Invited. Ochsner Medical Center. New Orleans, LA, US.
- 2006. Radiation Oncology Branch Grand Rounds. Invited. National Cancer Institute. Bethesda, MD, US.
- 2003. Grand Rounds. Invited. Grand Rounds, Columbus Children’s Research Institute Seminar Series. Columbus, OH, US.
- 2003. Pediatric Grand Rounds. Invited. Texas Children's Hospital. Houston, TX, US.
- 2003. Pediatric Oncology Grand Rounds. Invited. Memorial Sloan Kettering Cancer Center. New York, NY, US.
- 2002. Vascular Biology Seminar Series. Invited. Harvard Medical School. Boston, MA, US.
- 2002. The Elly & Jack Taylor Annual Oncology Lecture. Visiting. Mount Sinai Medical Center & Miami Heart Institute. Miami, FL, US.
- 2001. Cancer Research Seminar. Invited. Texas Children's Cancer Center. Houston, TX, US.
- 2001. Refresher Course Faculty. Visiting. 87th RSNA Scientific Assembly and Annual Meeting. Chicago, IL, US.
- 2001. Integrative Biology and Pharmacology Seminar Series. Invited. UT Medical School. Houston, TX, US.
- 2000. Visiting Professorship for Partners Urology Lecture Series. Visiting. Harvard Medical School. Boston, MA, US.
- 2000. Cancer Institute Symposium Series. Invited. St. Joseph's Cancer Institute. Tampa, FL, US.
- 2000. Grand Rounds. Invited. University of Pittsburgh Cancer Institute. Pittsburgh, PA, US.
- 1999. Seminars in Biomedical Sciences. Invited. University of California San Francisco. San Francisco, CA, US.
- 1999. Combined Pathology Grand Rounds. Invited. Beth Israel Deaconess Medical Center. Boston, MA, US.
- 1999. Fall Cancer Symposium. Invited. Divine Providence Hospital Cancer Center. Williamsport, PA, US.
- 1999. Harold W. Siebens Foundation Symposium. Invited. Mayo Clinic. Rochester, MN, US.
- 1999. Glover Day Conference. Invited. Deaconess-Glover Hospital. Needham, MA, US.
- 1999. Hematology/Oncology Grand Rounds. Invited. Scott & White Hospital. Temple, TX, US.
- 1999. Medicine Grand Rounds. Invited. Tufts University School of Medicine. Boston, MA, US.
- 1999. Vascular Biology Grand Rounds. Invited. Scripps Institute. La Jolla, CA, US.
- 1999. Medicine Grand Rounds. Invited. Newton Wellsley Hospital. Newton, MA, US.
- 1999. Vascular Biology Grand Rounds. Invited. Temple University Hospital. Philadelphia, PA, US.
- 1998. Human Gene Therapy Seminar Series. Invited. University of Pennsylvania. Philadelphia, PA, US.
- 1998. Oncology Grand Rounds. Invited. Fox Chase Cancer Center. Philadelphia, PA, US.
- 1998. Hematology/Oncology Grand Rounds. Invited. Beth Israel Deaconess Medical Center. Boston, MA, US.
- 1998. Medical Grand Rounds. Invited. Abington Memorial Hospital. Abington, PA, US.
- 1998. Pediatric Grand Rounds. Invited. New York University. New York, NY, US.
- 1997. Research Symposium. Invited. Gunma University. Maebashi, JP.
- 1997. Cancer Seminar. Invited. Dai-ichi Research Institute. Tokyo, JP.
- 1997. Cancer Seminar. Invited. Kirin Bioscience. Takasaki, JP.
- 1997. Cancer Symposium. Invited. Kyoto University. Kyoto, JP.
- 1996. Cancer Symposium. Invited. New Jersey Cancer Center. Hackensack, NJ, US.
- 1996. Anna Belsky Moranis Visiting Professorship of Medicine. Visiting. New York University. New York, NY, US.
- 1996. Research Seminar. Invited. Cleveland Clinic. Cleveland, OH, US.
- 1995. Seminar in Cancer Biology. Invited. Stonehill College. North Easton, MA, US.
- 1995. Metastasis and Cell Biology Seminar. Invited. University of Pittsburgh. Pittsburgh, PA, US.
- 1995. Medical Grand Rounds. Invited. Children's Hospital. Pittsburgh, PA, US.
- 1995. The Fibrinolytic System Symposium in honor of Kenneth Robbins. Invited. Northwestern University. Chicago, IL, US.
- 1995. Surgical Grand Rounds. Invited. Children's Hospital. Boston, MA, US.
- 1995. Guido Guidotti Lab Seminar. Invited. Harvard University. Boston, MA, US.
- 1995. Molecular and Vascular Biology Seminar. Invited. Katholieke Universiteit. Leuven, BE.
- 1995. General Surgery Grand Rounds. Invited. Allegheny General Hospital. Pittsburgh, PA, US.
- 1994. Sarcoma Conference Series. Invited. Dana Farber Cancer Institute. Boston, MA, US.
- 1993. Surgical Grand Rounds. Invited. Children's Hospital. Boston, MA, US.
Grant & Contract Support
| Date: | 2004 - 2009 |
| Title: | Extension of Radiotherapy Research, Project 3:Integration of Antiangiogenic Therapy with Radiation |
| Funding Source: | NCI |
| Role: | Project Leader |
| ID: | CA06294 |
| Date: | 2004 - 2018 |
| Title: | Proposal to evaluate the antiangiogenic, antivascular, and antitumor activities of ZD1839, ZD6474, AZD2171, and ZD6126 |
| Funding Source: | Astrazeneca |
| Role: | PI |
| ID: | LS2004-0001066LE |
| Date: | 2004 - 2018 |
| Title: | Maintenance therapy with molecular targeted agents after response to definitive chemoradiation therapy in orthotopic murine models of human lung cancer |
| Funding Source: | AstraZeneca |
| Role: | PI |
| ID: | AstraZeneca Research Collaboration Alliance |
| Date: | 2003 - 2008 |
| Title: | Phase I Studies of Targeted Anti-Cancer Therapies |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | U01-CA062461 |
| Date: | 2003 - Present |
| Title: | Robin L. Austin Fund Memorial |
| Funding Source: | Robin L. Austin Fund Memorial Fund |
| Role: | PI |
| Date: | 2002 - 2004 |
| Title: | Golfers Against Cancer Committee |
| Funding Source: | Golfers Against Cancer |
| Role: | PI |
| Date: | 2002 - 2005 |
| Title: | TARGET Lung Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | DAMD17-02-1-0706 |
| Date: | 2002 - Present |
| Title: | Antiangiogenic Strategies for Brain Metastasis |
| Funding Source: | Laura Nelson Trust Fund |
| Role: | PI |
| Date: | 2000 - 2000 |
| Title: | Targeted Molecular Diagnosis and Therapeutics |
| Funding Source: | Goodwin Fund |
| Role: | PI |
| ID: | unknown |
| Date: | 2000 - 2000 |
| Title: | Development Award, The University of Texas M. D. Anderson Cancer Center Support Grant |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | CA16672 |
Patient Reviews
CV information above last modified March 03, 2025